AXQ Capital LP Invests $36,000 in Q32 Bio Inc. (NASDAQ:QTTB)

AXQ Capital LP bought a new stake in Q32 Bio Inc. (NASDAQ:QTTB) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,581 shares of the company’s stock, valued at approximately $36,000. AXQ Capital LP owned 0.09% of Q32 Bio at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in QTTB. Monaco Asset Management SAM acquired a new position in shares of Q32 Bio in the fourth quarter valued at about $1,977,000. Raymond James Financial Inc. purchased a new stake in Q32 Bio in the fourth quarter valued at approximately $37,000. Hussman Strategic Advisors Inc. acquired a new position in Q32 Bio in the 4th quarter worth approximately $36,000. Rhumbline Advisers raised its position in Q32 Bio by 1,164.3% during the 4th quarter. Rhumbline Advisers now owns 105,544 shares of the company’s stock worth $363,000 after buying an additional 97,196 shares during the last quarter. Finally, Savant Capital LLC acquired a new stake in Q32 Bio during the 4th quarter valued at approximately $53,000. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Q32 Bio Stock Performance

NASDAQ QTTB opened at $2.18 on Tuesday. The stock has a market capitalization of $26.59 million, a price-to-earnings ratio of -0.15 and a beta of -0.27. The stock has a 50-day moving average of $2.68 and a 200 day moving average of $21.11. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.61. Q32 Bio Inc. has a twelve month low of $1.80 and a twelve month high of $53.79.

Q32 Bio (NASDAQ:QTTB) last announced its earnings results on Tuesday, March 11th. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.09. Sell-side analysts anticipate that Q32 Bio Inc. will post -12.32 EPS for the current fiscal year.

Analyst Ratings Changes

QTTB has been the topic of a number of research reports. Wells Fargo & Company cut their price objective on shares of Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 12th. Raymond James reiterated an “outperform” rating and set a $22.00 price objective (down previously from $90.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Leerink Partners restated a “market perform” rating and issued a $9.00 target price (down previously from $68.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Guggenheim lowered Q32 Bio from a “buy” rating to a “neutral” rating in a report on Wednesday, December 11th. Finally, BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $22.00 to $3.00 in a report on Tuesday, February 11th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $24.71.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.